Indegene Revenue Surges 24% in FY26; Net Profit Dips to ₹401 Cr Amid Acquisition Costs
Synopsis: India's largest life sciences commercialisation company has simultaneously watched its full-year net profit slip 1.4 percent to Rs. 401 crore, as acquisition-related depreciation, a TCPA litigation settlement provision, and integration expenses absorbed the topline gains. A Bengaluru-based digital-first life sciences commercialisation company came into focus on April 29, 2026, after its board approved audited standalone and consolidated financial results…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
